Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Martek Biosciences Corp.

(MATK)

Bear, Stearns analyst Scott Shevick began coverage with a "hold." The company's products

Read the full 178 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE